1-20 of 136
David S. Siegel
Close
Sort by
Journal Articles

Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar
Journal: Blood
Blood (2023) 142 (Supplement 1): 6930.
https://doi.org/10.1182/blood-2023-190413
Published: 2023
Journal Articles

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Kimberly Doucette, Rena Feinman, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Lisa Biamonte, Martha Campanaro, Trina McClendon, Chandani Limbad, Samanta BaboolallAracena, Adolfo Aleman, Rashmi Unawane, Elizabeth Pendergrass, Marie Layton, Genevieve Breeze, Aimee Chappell, Alexandra Della Pia, Susan Kumka, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6714.
https://doi.org/10.1182/blood-2023-187011
Published: 2023
Journal Articles

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Samuel Roy, Katelyn Quino, Noreen Ahmed, Adolfo Aleman, Rashmi Unawane, Joshua Zenreich, Alana Barofsky, Kashish Bhatt, Michele L. Donato, Noa Biran, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3294.
https://doi.org/10.1182/blood-2023-190108
Published: 2023
Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Jesus G. Berdeja, David Dingli, Sagar Lonial, Andrew J. Yee, Alfred Chung, Cristina Gasparetto, P. Leif Bergsagel, Vivek Roy, Al-Ola Abdallah, Sharmilan Thanendrarajan, Aimaz Afrough, Laura Rosiñol, Suzanne Trudel, Paula Rodriguez Otero, Cyrille Touzeau, Pierre Bories, Soo Bang, Terry Connolly, Michelle Kim, Chad A. Lewis, Bao-Van Tran Linberg, M. Travis Quigley, Ola Landgren, Saad Z Usmani, Maria-Victoria Mateos, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3391.
https://doi.org/10.1182/blood-2023-174550
Published: 2023
Journal Articles

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Kimberly Doucette, Rena Feinman, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Lisa Biamonte, Martha Campanaro, Trina McClendon, Chandani Limbad, Samanta BaboolallAracena, Adolfo Aleman, Rashmi Unawane, Elizabeth Pendergrass, Marie Layton, Genevieve Breeze, Aimee Chappell, Alexandra Della Pia, Susan Kumka, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2022.
https://doi.org/10.1182/blood-2023-189907
Published: 2023
Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3386.
https://doi.org/10.1182/blood-2023-180761
Published: 2023
Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2013.
https://doi.org/10.1182/blood-2023-181905
Published: 2023
Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Madhav V. Dhodapkar, Melissa Alsina, Jesus G. Berdeja, Krina K. Patel, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Laurie Eliason, Xiaobo Zhong, Chiara Greggio, Sinhan Tran, Maria Chaudhry, Marlene J. Carrasco-Alfonso, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2101.
https://doi.org/10.1182/blood-2023-173970
Published: 2023
Journal Articles

Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

Meletios Athanasios Dimopoulos, Ola Landgren, David S. Siegel, Sebastian Grosicki, Albert Oriol, Rani Najdi, Chuang Li, Khalid Mezzi, Natalie Shu, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 2021.
https://doi.org/10.1182/blood-2023-190726
Published: 2023
Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies
Journal: Blood
Blood (2023) 142 (Supplement 1): 4741.
https://doi.org/10.1182/blood-2023-181304
Published: 2023
Journal Articles

Single-Center Experience of Carfilzomib-Based Combinations for Patients with Lymphoplasmacytic Lymphoma

Harsh Parmar, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1684.
https://doi.org/10.1182/blood-2023-190155
Published: 2023
Journal Articles

Using Next Generation Sequencing of Flow Cytometry CD Markers and Machine Learning As a Replacement to Flow Cytometry Analysis for the Diagnosis of Hematologic Neoplasms

Maher Albitar, Hong Zhang, Andrew Ip, Wanlong Ma, James McCloskey, Katherine Linder, Jeffrey Justin Estella, Jamie Koprivnikar, Noa Biran, David S. Siegel, Ahmad Charifa, Arash Mohtashamian, Andrew L Pecora, Andre Goy
Journal: Blood
Blood (2023) 142 (Supplement 1): 3654.
https://doi.org/10.1182/blood-2023-187041
Published: 2023
Journal Articles

A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar
Journal: Blood
Blood (2023) 142 (Supplement 1): 4717.
https://doi.org/10.1182/blood-2023-190583
Published: 2023
Journal Articles

Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, Sukhdeep Kaur, Hyung C Suh, Christina Cho, Michele L. Donato, Scott D Rowley, David H. Vesole, David S. Siegel, Harsh Parmar
Journal: Blood
Blood (2023) 142 (Supplement 1): 6903.
https://doi.org/10.1182/blood-2023-190507
Published: 2023
Journal Articles

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur S. Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina
Journal: Blood
Blood (2021) 138 (Supplement 1): 548.
https://doi.org/10.1182/blood-2021-146518
Published: 2021
Journal Articles

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Michaela Liedtke, Surbhi Sidana, Jeffrey V. Matous, Saurabh Chhabra, Olalekan O. Oluwole, Shahbaz A. Malik, Shaji Kumar, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Sundar Jagannath, Myo Htut, Noopur S. Raje, David S. Siegel, Erin E. Karski, Wade Lovelace, Afrodite Lourbakos, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 651.
https://doi.org/10.1182/blood-2021-145572
Published: 2021
Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Barry Paul, Michaela Liedtke, Jorge Monge, Maria Chaudhry, Robert M. Rifkin, Mitul D. Gandhi, Jack Khouri, Andrew Kin, Tibor Kovacsovics, Moshe Y. Levy, Ann Mohrbacher, William Schmidt, David S. Siegel, Rebecca W. Silbermann, Anna Louise Byrne, Tina Ncube, Michael Murphy, Lin Gu, Nishanthan Rajakumaraswamy, Mark Chao, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2021-145903
Published: 2021
Journal Articles

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Caitlin Costello, Ben A Derman, Mehmet Hakan Kocoglu, Abhinav Deol, Abbas Abbas Ali, Tara Gregory, Bhagirathbhai Dholaria, Jesus G Berdeja, Adam D Cohen, Krina K. Patel, David S. Siegel, Rajneesh Nath, Katherine McArthur, Joanne McCaigue, Christopher E Martin, Majid Ghoddusi, Hamid Namini, Eric M. Ostertag, Matthew A. Spear, Rajesh Belani, Nina Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 3858.
https://doi.org/10.1182/blood-2021-151672
Published: 2021
Journal Articles

Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

Sarvarinder K Gill, Rashmi Unawane, Shuqi Wang, Adolfo Aleman, Michelle Serna, Fideliza Perez-Manon, Gina Rivieccio, David S. Siegel, David H. Vesole, Harsh Parmar, Jaeil Ahn, Noa Biran
Journal: Blood
Blood (2021) 138 (Supplement 1): 4742.
https://doi.org/10.1182/blood-2021-153556
Published: 2021
Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134189
Published: 2020